Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2015 Oct 15;10(10):e0140068.
doi: 10.1371/journal.pone.0140068. eCollection 2015.

Non-Invasive Evaluation of Hepatic Fibrosis: The Diagnostic Performance of Magnetic Resonance Elastography in Patients with Viral Hepatitis B or C

Affiliations
Comparative Study

Non-Invasive Evaluation of Hepatic Fibrosis: The Diagnostic Performance of Magnetic Resonance Elastography in Patients with Viral Hepatitis B or C

Wen-Pei Wu et al. PLoS One. .

Abstract

Purpose: To compare the accuracy of magnetic resonance elastography (MRE) with that of aspartate aminotransferase-to-platelet ratio index (APRI) for estimating the stage of hepatic fibrosis in patients with chronic hepatitis B virus (HBV) or chronic hepatitis C virus (HCV) infection.

Materials and methods: We retrospectively enrolled 160 patients with chronic hepatitis and 25 healthy living liver donors. Fibrosis stage (METAVIR, F0 to F4) was determined histopathologically for all patients. APRI was recorded at the time of histopathologic examination and liver stiffness values were measured on MRE quantitative stiffness maps. The cutoff values, sensitivity, and specificity of MRE and APRI for each fibrosis stage were determined using receiver operating characteristic (ROC) analysis.

Results: MRE had a significantly greater area under the ROC curve than APRI score for discriminating among METAVIR stages F2-F4. Using a cutoff value of 2.80 kPa, MRE had a sensitivity of 94.4% and a specificity of 97.8% for detecting significant fibrosis (≥F2). There were no significant differences in fibrosis stage between patients with HBV and those with HCV infection. For ≥F2, the cutoffs were 2.47 kPa (100% sensitivity), 2.80 kP (maximum sum of sensitivity and specificity), and 3.70 kPa (100% specificity).

Conclusions: MRE is a more accurate modality than APRI for detecting significant fibrosis in patients with chronic HBV or HCV infection. Antiviral treatment should be considered in patients with liver stiffness values ≥ 2.8 kPa.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. Flow diagram of patient selection.
HBV = chronic hepatitis B; HCV = chronic hepatitis C; APRI = aspartate aminotransferase to the platelet ratio index; MRE = MR elastography.
Fig 2
Fig 2. MRE data in a 46-year-old female with hepatitis B.
(a) magnitude image,.(b) wave image, (c) stiffness map, and (d) confidence map. All images are at the same level. The dotted lines on the confidence maps represent the liver outlines of the corresponding patient’s MR images. The overall mean stiffness value on a total of 5 MRE images was 2.34 kPa. Liver biopsy confirmed fibrosis stage F1.
Fig 3
Fig 3. Box plots.
(a) liver stiffness values measured by MRE and (b) APRI values according to each METAVIR fibrosis stage (F0 to F4). The mean liver stiffness scores and APRI values increased with increasing METAVIR stage of fibrosis. (Spearman’s risk correlation coefficient = 0.85 and 0.42, respectively) The horizontal line through each box represents the median and each box represents data from the 25th to the 75th percentile. The separate asterisks and circles represent outliers.
Fig 4
Fig 4. Proposed clinical algorithm of liver stiffness measured by MR Elastography in patients with HBV and those with HCV.

References

    1. Hoofnagle JH, Doo E, Liang TJ, Fleischer R, Lok AS. Management of hepatitis B: summary of a clinical research workshop. Hepatology. 2007;45(4):1056–75. Epub 2007/03/30. 10.1002/hep.21627 . - DOI - PubMed
    1. Puoti C, Guarisco R, Bellis L, Spilabotti L. Diagnosis, management, and treatment of hepatitis C. Hepatology. 2009;50(1):322; author reply 4–5. Epub 2009/05/28. 10.1002/hep.23015 . - DOI - PubMed
    1. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrsopoulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol. 2002;97(10):2614–8. Epub 2002/10/19. 10.1111/j.1572-0241.2002.06038.x . - DOI - PubMed
    1. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology. 2003;38(6):1449–57. 10.1016/j.hep.2003.09.022 . - DOI - PubMed
    1. Bohte AE, de Niet A, Jansen L, Bipat S, Nederveen AJ, Verheij J, et al. Non-invasive evaluation of liver fibrosis: a comparison of ultrasound-based transient elastography and MR elastography in patients with viral hepatitis B and C. Eur Radiol. 2014;24(3):638–48. Epub 2013/10/26. 10.1007/s00330-013-3046-0 . - DOI - PubMed

Publication types

MeSH terms

Substances